Formulation Development

Next-generation fluorescent imaging solution for the assurance of monoclonality and automated confluence across diverse cell types

Demonstrating that cell lines are monoclonal – or that a gene was edited as expected – can be a time-consuming and highly-subjective process when relying on conventional technologies. The CloneSelect® Imager and CloneSelect® Imager FL are a high-throughput automated solutions for imaging and analyzing mammalian cells. Tracking the formation of a colony from a single cell is effortless as barcoded plates are tracked over time. Automated acquisition and analysis provides accurate, objective, and consistent results.

The Percepta Platform is a portfolio of software applications and a technology ecosystem for predicting and managing physicochemical, ADME/Tox, and other molecular property data.

With Percepta applications you can predict molecular properties from structure, and train models with experimental data. You can even include custom models created in-house to centrally manage in silico calculations and training sets for distribution so that everyone calculating property data is using up-to-date information.

Access the future of AI microscopy

Subjectivity of analysis and poor reproducibility are key hurdles to be overcome for biological image analysis. Standard segmentation can lead to sub-standard results and require substantial manual curation which is subject to human error.

The Powder Rheology Accessory expands the DHR’s capabilities to powders, enabling the characterization of behaviors during storage, dispensing, processing, and end-use.

Whether you require a particular expertise or a complete, experienced integrated small molecule discovery team, Curia can provide a high-performance solution to help turn your vision into reality.

Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels due to inadequate insulin production or impaired insulin utilization, commonly known as insulin resistance.

Upperton offers formulation development services to accelerate First-in-Human studies and advance projects toward clinical trials.

The systems can be provided in sterile, toxic or sterile toxic arrangements with the great advantage of being 100 % scalable.